SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

David Planchard

David Planchard

Gustave Roussy, Villejuif

Dr. David Planchard is a thoracic oncologist and Professor who heads the Thoracic Group in the Department of Medical Oncology at Gustave Roussy in Villejuif, France, and chairs its International Centre for Thoracic Cancers. His clinical and translational work focuses on non-small cell lung cancer, pleural mesothelioma and thymic tumours, with expertise in predictive biomarkers, targeted therapy and immunotherapy for oncogene-driven disease.

He led the pivotal phase II trials of dabrafenib plus trametinib that established BRAF/MEK inhibition in BRAF V600E-mutant NSCLC, and contributes to research on HER2-directed therapies and antibody-drug conjugates. He coordinated the ESMO Clinical Practice Guidelines for metastatic NSCLC and belongs to ESMO, ASCO, AACR and the French thoracic oncology intergroup (IFCT).

Connect

David Planchard

Featured in

Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

Read the article

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

Read the article

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 01 2026
RESEARCH
Targeted Therapies

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

Read the article

B. RicciutiJ. RemonD. Planchard
Sep 17 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

Read the article

D. Planchard
Aug 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

Read the article

M. HochmairH. HorinouchiD. Planchard
Aug 21 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

A ctDNA tumour fraction of 5% or more marks who benefits from adding chemotherapy to checkpoint blockade

Read the article

D. Planchard
Jul 15 2026
RESEARCH
Advanced NSCLCImmunotherapies

Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC

Read the article

A. CortelliniD. PlanchardJ. NaidooJ. RemonB. Ricciuti
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

The International Lung Cancer Summit returns on 13 November 2026 – on site in Lausanne and streamed online. A one-day programme of practice-changing lung cancer debates, chaired by Solange Peters and Alfredo ...

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans